|
1
|
Yan Y, Xu Z, Qian L, Zeng S, Zhou Y, Chen
X, Wei J and Gong Z: Identification of CAV1 and DCN as potential
predictive biomarkers for lung adenocarcinoma. Am J Physiol Lung
Cell Mol Physiol. 316:L630–L643. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zheng H, Zhan Y, Liu S, Lu J, Luo J, Feng
J and Fan S: The roles of tumor-derived exosomes in non-small cell
lung cancer and their clinical implications. J Exp Clin Cancer Res.
37:2262018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zugazagoitia J, Ponce S and Paz-Ares L:
Necitumumab for first-line treatment of advanced, squamous,
non-small-cell lung cancer: A relevant step forward? Transl Lung
Cancer Res. 5:95–97. 2016.PubMed/NCBI
|
|
6
|
Drilon A, Rekhtman N, Ladanyi M and Paik
P: Squamous-cell carcinomas of the lung: Emerging biology,
controversies and the promise of targeted therapy. Lancet Oncol.
13:e418–e426. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yan Y, Xu Z, Hu X, Qian L, Li Z, Zhou Y,
Dai S, Zeng S and Gong Z: SNCA is a functionally low-expressed gene
in lung adenocarcinoma. Genes. 9(pii): E162018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tan WL, Jain A, Takano A, Newell EW, Iyer
NG, Lim WT, Tan EH, Zhai W, Hillmer AM, Tam WL and Tan DSW: Novel
therapeutic targets on the horizon for lung cancer. Lancet Oncol.
17:e347–e362. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang C, Zou J, Ma X, Wang E and Peng G:
Mechanisms and implications of ADAR-mediated RNA editing in cancer.
Cancer Lett. 411:27–34. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peng L, Zhang H, Su Y, Shen Q, Du C, Xie
H, Li H, Yan J, Shen Z, Jiang W, et al: Lipopolysaccharide enhances
ADAR2 which drives Hirschsprung's disease by impairing miR-142-3p
biogenesis. J Cell Mol Med. 22:4045–4055. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen YB, Liao XY, Zhang JB, Wang F, Qin
HD, Zhang L, Shugart YY, Zeng YX and Jia WH: ADAR2 functions as a
tumor suppressor via editing IGFBP7 in esophageal squamous cell
carcinoma. Int J Oncol. 50:622–630. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen YT, Chang IY, Liu H, Ma CP, Kuo YP,
Shih CT, Shih YH, Kang L and Tan BC: Tumor-associated intronic
editing of HNRPLL generates a novel splicing variant linked to cell
proliferation. J Biol Chem. 293:10158–10171. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuner R, Muley T, Meister M, Ruschhaupt M,
Buness A, Xu EC, Schnabel P, Warth A, Poustka A, Sültmann H and
Hoffmann H: Global gene expression analysis reveals specific
patterns of cell junctions in non-small cell lung cancer subtypes.
Lung Cancer. 63:32–38. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Barrett T and Edgar R: Reannotation of
array probes at NCBI's GEO database. Nat Methods. 5:1172008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang Z, Li C, Zhang K, Yang M and Hu X:
GE-mini: A mobile APP for large-scale gene expression
visualization. Bioinformatics. 33:941–943. 2017.PubMed/NCBI
|
|
16
|
Barretina J, Caponigro G, Stransky N,
Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV,
Sonkin D, et al: The cancer cell line encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature.
483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Diez-Villanueva A, Mallona I and Peinado
MA: Wanderer, an interactive viewer to explore DNA methylation and
gene expression data in human cancer. Epigenetics Chromatin.
8:222015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xiong Y, Wei Y, Gu Y, Zhang S, Lyu J,
Zhang B, Chen C, Zhu J, Wang Y, Liu H and Zhang Y: DiseaseMeth
version 2.0: A major expansion and update of the human disease
methylation database. Nucleic Acids Res. 45:D888–D895. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Modhukur V, Iljasenko T, Metsalu T, Lokk
K, Laisk-Podar T and Vilo J: MethSurv: A web tool to perform
multivariable survival analysis using DNA methylation data.
Epigenomics. 10:277–288. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cancer Genome Atlas Research Network, .
Comprehensive genomic characterization of squamous cell lung
cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45:D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Reimand J, Isserlin R, Voisin V, Kucera M,
Tannus-Lopes C, Rostamianfar A, Wadi L, Meyer M, Wong J, Xu C, et
al: Pathway enrichment analysis and visualization of omics data
using g:Profiler, GSEA, Cytoscape and EnrichmentMap. Nat Protoc.
14:482–517. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kanehisa M, Furumichi M, Tanabe M, Sato Y
and Morishima K: KEGG: New perspectives on genomes, pathways,
diseases and drugs. Nucleic Acids Res. 45:D353–D361. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang J, Vasaikar S, Shi Z, Greer M and
Zhang B: WebGestalt 2017: A more comprehensive, powerful, flexible
and interactive gene set enrichment analysis toolkit. Nucleic Acids
Res. 45:W130–W137. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang L, Liu L, Xu Z, Liao W, Feng D, Dong
X, Xu S, Xiao L, Lu J, Luo X, et al: EBV-LMP1 targeted DNAzyme
enhances radiosensitivity by inhibiting tumor angiogenesis via the
JNKs/HIF-1 pathway in nasopharyngeal carcinoma. Oncotarget.
6:5804–5817. 2015.PubMed/NCBI
|
|
31
|
Wang X, Xu Z, Ren X, Chen X, Wei J, Lin W,
Li Z, Ou C, Gong Z and Yan Y: Function of low ADARB1 expression in
lung adenocarcinoma. PLoS One. 14:e02222982019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou S, Yan Y, Chen X, Wang X, Zeng S,
Qian L, Wei J, Yang X, Zhou Y, Gong Z and Xu Z: Roles of highly
expressed PAICS in lung adenocarcinoma. Gene. 692:1–8. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xiao D, Lu C, Zhu W, He Q, Li Y, Fu C,
Zhou J, Liu S and Tao Y: Comparison of small biopsy specimens and
surgical specimens for the detection of EGFR mutations and EML4-ALK
in non-small-cell lung cancer. Oncotarget. 7:59049–59057. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gan Z, Zhao L, Yang L, Huang P, Zhao F, Li
W and Liu Y: RNA editing by ADAR2 is metabolically regulated in
pancreatic islets and beta-cells. J Biol Chem. 281:33386–33394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li Z, Tian Y, Tian N, Zhao X, Du C, Han L
and Zhang H: Aberrant alternative splicing pattern of ADAR2
downregulates adenosine-to-inosine editing in glioma. Oncol Rep.
33:2845–2852. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Merkle T, Merz S, Reautschnig P, Blaha A,
Li Q, Vogel P, Wettengel J, Li JB and Stafforst T: Precise RNA
editing by recruiting endogenous ADARs with antisense
oligonucleotides. Nat Biotechnol. 37:133–138. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kuang L, Lv G, Wang B, Li L, Dai Y and Li
Y: Overexpression of adenosine deaminase acting on RNA 1 in
chordoma tissues is associated with chordoma pathogenesis by
reducing miR125a and miR10a expression. Mol Med Rep. 12:93–98.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hosaka T, Yamashita T, Teramoto S, Hirose
N, Tamaoka A and Kwak S: ADAR2-dependent A-to-I RNA editing in the
extracellular linear and circular RNAs. Neurosci Res. 147:48–57.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fritzell K, Xu LD, Lagergren J and Öhman
M: ADARs and editing: The role of A-to-I RNA modification in cancer
progression. Semin Cell Dev Biology. 79:123–130. 2018. View Article : Google Scholar
|
|
40
|
Chan TH, Qamra A, Tan KT, Guo J, Yang H,
Qi L, Lin JS, Ng VH, Song Y, Hong H, et al: ADAR-Mediated RNA
editing predicts progression and prognosis of gastric cancer.
Gastroenterology. 151:637–650.e10. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Altadill T, Dowdy TM, Gill K, Reques A,
Menon SS, Moiola CP, Lopez-Gil C, Coll E, Matias-Guiu X, Cabrera S,
et al: Metabolomic and Lipidomic profiling identifies the role of
the RNA editing pathway in endometrial carcinogenesis. Sci Rep.
7:88032017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Uchida H, Matsumura S, Okada S, Suzuki T,
Minami T and Ito S: RNA editing enzyme ADAR2 is a mediator of
neuropathic pain after peripheral nerve injury. FASEB J.
31:1847–1855. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Galeano F, Rossetti C, Tomaselli S,
Cifaldi L, Lezzerini M, Pezzullo M, Boldrini R, Massimi L, Di Rocco
CM, Locatelli F and Gallo A: ADAR2-editing activity inhibits
glioblastoma growth through the modulation of the
CDC14B/Skp2/p21/p27 axis. Oncogene. 32:998–1009. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen M, Liu X, Du J, Wang XJ and Xia L:
Differentiated regulation of immune-response related genes between
LUAD and LUSC subtypes of lung cancers. Oncotarget. 8:133–144.
2017.PubMed/NCBI
|
|
45
|
Planchard D, Popat S, Kerr K, Novello S,
Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD
and Peters S: Metastatic non-small cell lung cancer: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 30:863–870. 2019. View Article : Google Scholar
|
|
46
|
Bishop JA, Teruya-Feldstein J, Westra WH,
Pelosi G, Travis WD and Rekhtman N: p40 (ΔNp63) is superior to p63
for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol.
25:405–415. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: Introduction to The 2015 World Health
Organization classification of tumors of the lung, pleura, thymus,
and heart. J Thorac Oncol. 10:1240–1242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kriegsmann K, Cremer M, Zgorzelski C,
Harms A, Muley T, Winter H, Kazdal D, Warth A and Kriegsmann M:
Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell
lung cancer. Pathology. 51:240–245. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
van Zyl A, Schubert PT and Koegelenberg
CFN: The utility of TTF-1, napsin A, CK5 and p63 staining in the
sub-classification of non-small cell carcinoma of the lung.
Cytopathology. 30:586–591. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang Y, Han Y, Guo Z, Yang Y and Ren T:
Nuclear TAZ activity distinctly associates with subtypes of
non-small cell lung cancer. Biochem Biophys Res Commun.
509:828–832. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hou J, Aerts J, den Hamer B, van Ijcken W,
den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens
JA, Hoogsteden HC, et al: Gene expression-based classification of
non-small cell lung carcinomas and survival prediction. PLoS One.
5:e103122010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Takamochi K, Ohmiya H, Itoh M, Mogushi K,
Saito T, Hara K, Mitani K, Kogo Y, Yamanaka Y, Kawai J, et al:
Novel biomarkers that assist in accurate discrimination of squamous
cell carcinoma from adenocarcinoma of the lung. BMC Cancer.
16:7602016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lipsick J: A history of cancer research:
Tyrosine kinases. Cold Spring Harb Perspect Biol. 11(pii):
a0355922019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Martinez P, Peters S, Stammers T and Soria
JC: Immunotherapy for the First-line treatment of patients with
metastatic non-small cell lung cancer. Clin Cancer Res.
25:2691–2698. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Liu Y, Jiang H, Zhou H, Ying X, Wang Z,
Yang Y, Xu W, He X and Li Y: Lentivirus-mediated silencing of
HOTAIR lncRNA restores gefitinib sensitivity by activating
Bax/Caspase-3 and suppressing TGF-α/EGFR signaling in lung
adenocarcinoma. Oncol Lett. 15:2829–2838. 2018.PubMed/NCBI
|
|
56
|
Romero-Ventosa EY, Blanco-Prieto S,
Gonzalez-Pineiro AL, Rodriguez-Berrocal FJ, Pineiro-Corrales G and
Paez de la Cadena M: Pretreatment levels of the serum biomarkers
CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF,
TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated
non-small-cell lung cancer patients. Springerplus. 4:1712015.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gao J, Qiu X, Xi G, Liu H, Zhang F, Lv T
and Song Y: Downregulation of GSDMD attenuates tumor proliferation
via the intrinsic mitochondrial apoptotic pathway and inhibition of
EGFR/Akt signaling and predicts a good prognosis in non-small cell
lung cancer. Oncol Rep. 40:1971–1984. 2018.PubMed/NCBI
|
